Literature DB >> 33270090

Teprotumumab for Optic Neuropathy in Thyroid Eye Disease.

Dane H Slentz1,2, Terry J Smith1,3, Denise S Kim1, Shannon S Joseph1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33270090     DOI: 10.1001/jamaophthalmol.2020.5296

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  9 in total

Review 1.  2021 update on thyroid-associated ophthalmopathy.

Authors:  E J Neag; T J Smith
Journal:  J Endocrinol Invest       Date:  2021-08-20       Impact factor: 5.467

2.  Teprotumumab (Tepezza) for Thyroid Eye Disease.

Authors:  Steven M Couch
Journal:  Mo Med       Date:  2022 Jan-Feb

3.  Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.

Authors:  Roshini Fernando; Oshadi Caldera; Terry J Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-28       Impact factor: 12.779

Review 4.  Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-17       Impact factor: 5.555

5.  Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases.

Authors:  Carolina A Chiou; Edith R Reshef; Suzanne K Freitag
Journal:  Am J Ophthalmol Case Rep       Date:  2021-03-17

6.  Thyroid Eye Disease: Navigating the New Treatment Landscape.

Authors:  Chrysoula Dosiou; Andrea Lora Kossler
Journal:  J Endocr Soc       Date:  2021-03-17

Review 7.  Thyroid eye disease: From pathogenesis to targeted therapies.

Authors:  Jin Sook Yoon; Don O Kikkawa
Journal:  Taiwan J Ophthalmol       Date:  2022-01-21

Review 8.  Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.

Authors:  Caroline Y Yu; Rebecca L Ford; Sara T Wester; Erin M Shriver
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

Review 9.  Insulin-Like Growth Factor Pathway and the Thyroid.

Authors:  Terry J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.